Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Mini-Review Article

优化丹曲林神经保护治疗阿尔茨海默病的方法

卷 17, 期 4, 2020

页: [324 - 328] 页: 5

弟呕挨: 10.2174/1567205017666200522204722

价格: $65

conference banner
摘要

阿尔茨海默病(AD)是一种发病率和死亡率都很高的神经退行性疾病，在没有有效的疾病治疗药物的情况下，它正成为最致命的疾病。Ca2+失调，特别是Ca2+通过过度激活ryanodine受体(RyR)的异常释放，已被越来越多地认为是AD病理中另一种上游机制。因此，dantrolene，一种RyR拮抗剂和FDA批准的用于治疗恶性热疗和慢性肌肉痉挛的药物，已被证明可以改善AD转基因小鼠的记忆损失。但丹洛林在AD等神经退行性疾病中的剂量依赖性神经保护作用有待解决dantrolene在通过血脑屏障(BBB)并穿透中枢神经系统方面效率低下的问题。在这篇简短的综述中，我们将讨论dantrolene在AD治疗中的神经保护现状，以及最大化其有益作用的策略，如鼻内给药dantrolene。

关键词: 阿尔兹海默症

« Previous Next »
[1]
Rapid growth in neuroscience research: A study of neuroscience papers from 2006-2015 has revealed the most productive journals and contributing countries, and the most popular research topics [Internet]ScienceDaily 2019[cited 23 June 2019] Available from https://www.sciencedaily.com/releases/2017/04/170420093736.htm
[2]
Stocum D. Regenerative medicine of neural tissues. In: Regen Biol Med. 2012; pp. 285-323.
[3]
Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: An appraisal from 1984 to 2014. J Intern Med 2014; 275(3): 251-83.
[http://dx.doi.org/10.1111/joim.12191] [PMID: 24605808]
[4]
Khachaturian ZS. Calcium hypothesis of Alzheimer’s disease and brain aging. Ann N Y Acad Sci 1994; 747(1): 1-11.
[http://dx.doi.org/10.1111/j.1749-6632.1994.tb44398.x] [PMID: 7847664]
[5]
Reitz C. Alzheimer’s disease and the amyloid cascade hypothesis: A critical review. Int J Alzheimers Dis 2012; 2012: 369808.
[http://dx.doi.org/10.1155/2012/369808] [PMID: 22506132]
[6]
Selkoe DJ. Alzheimer disease and aducanumab: Adjusting our approach. Nat Rev Neurol 2019; 15(7): 365-6.
[http://dx.doi.org/10.1038/s41582-019-0205-1] [PMID: 31138932]
[7]
Feuerstein A. Biogen halts studies of closely watched alzheimer’s drug, a blow to hopes for new treatment 2019.https://www.scientificamerican.com/article/biogen-halts-studies-of-closely-watched-alzheimers-drug-a-blow-to-hopes-for-new-treatment/?redirect=1
[8]
Mullane K, Williams M. Alzheimer’s therapeutics: Continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 2013; 85(3): 289-305.
[http://dx.doi.org/10.1016/j.bcp.2012.11.014] [PMID: 23178653]
[9]
Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci 2008; 31(9): 454-63.
[http://dx.doi.org/10.1016/j.tins.2008.06.005] [PMID: 18675468]
[10]
Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer’s disease. Expert Opin Pharmacother 2009; 10(10): 1657-64.
[http://dx.doi.org/10.1517/14656560903044982] [PMID: 19527190]
[11]
Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012; 69(11): 1430-40.
[http://dx.doi.org/10.1001/archneurol.2012.2194] [PMID: 22892585]
[12]
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 2001; 98(15): 8850-5.
[http://dx.doi.org/10.1073/pnas.151261398] [PMID: 11438712]
[13]
Doody RS, Raman R, Farlow M, et al. Alzheimer’s Disease Cooperative Study Steering Committee Semagacestat Study Group. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 2013; 369(4): 341-50.
[http://dx.doi.org/10.1056/NEJMoa1210951] [PMID: 23883379]
[14]
Liang L, Wei H. Dantrolene, a treatment for Alzheimer disease? Alzheimer Dis Assoc Disord 2015; 29(1): 1-5.
[http://dx.doi.org/10.1097/WAD.0000000000000076] [PMID: 25551862]
[15]
Wang Y, Shi Y, Wei H. calcium dysregulation in alzheimer’s disease: A target for new drug development. J Alzheimers Dis Parkinsonism 2017; 7(5): 374.
[http://dx.doi.org/10.4172/2161-0460.1000374] [PMID: 29214114]
[16]
Tong BC, Wu AJ, Li M, Cheung KH. Calcium signaling in Alzheimer’s disease & therapies. Biochim Biophys Acta Mol Cell Res 2018; 1865(11 Pt B): 1745-60.
[http://dx.doi.org/10.1016/j.bbamcr.2018.07.018] [PMID: 30059692]
[17]
Choi RH, Koenig X, Launikonis BS. Dantrolene requires Mg2+ to arrest malignant hyperthermia. Proc Natl Acad Sci USA 2017; 114(18): 4811-5.
[http://dx.doi.org/10.1073/pnas.1619835114] [PMID: 28373535]
[18]
Copenhaver PF, Anekonda TS, Musashe D, et al. A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: Isradipine as a candidate drug. Dis Model Mech 2011; 4(5): 634-48.
[http://dx.doi.org/10.1242/dmm.006841] [PMID: 21596710]
[19]
Berridge MJ. Calcium hypothesis of Alzheimer’s disease. J Physiol 2009; 459(3): 441-9.
[20]
Wang J, Ono K, Dickstein DL, et al. Carvedilol as a potential novel agent for the treatment of Alzheimer’s disease. Neurobiol Aging 2011; 32(12): 2321.e1-2321.e12.
[http://dx.doi.org/10.1016/j.neurobiolaging.2010.05.004] [PMID: 20579773]
[21]
Bloss EB, Hunter RG, Waters EM, Munoz C, Bernard K, McEwen BS. Behavioral and biological effects of chronic S18986, a positive AMPA receptor modulator, during aging. Exp Neurol 2008; 210(1): 109-17.
[http://dx.doi.org/10.1016/j.expneurol.2007.10.007] [PMID: 18035355]
[22]
Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer’s disease: Focus on disease modifying drugs. Br J Clin Pharmacol 2012; 73(4): 504-17.
[http://dx.doi.org/10.1111/j.1365-2125.2011.04134.x] [PMID: 22035455]
[23]
Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59(4): 364-73.
[http://dx.doi.org/10.1111/j.1365-2044.2004.03658.x] [PMID: 15023108]
[24]
Oulès B, Del Prete D, Greco B, et al. Ryanodine receptor blockade reduces amyloid-β load and memory impairments in Tg2576 mouse model of Alzheimer disease. J Neurosci 2012; 32(34): 11820-34.
[http://dx.doi.org/10.1523/JNEUROSCI.0875-12.2012] [PMID: 22915123]
[25]
Peng J, Liang G, Inan S, et al. Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. Neurosci Lett 2012; 516(2): 274-9.
[http://dx.doi.org/10.1016/j.neulet.2012.04.008] [PMID: 22516463]
[26]
Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I. Role of presenilins in neuronal calcium homeostasis. J Neurosci 2010; 30(25): 8566-80.
[http://dx.doi.org/10.1523/JNEUROSCI.1554-10.2010] [PMID: 20573903]
[27]
Wu Z, Yang B, Liu C, et al. Long-term dantrolene treatment reduced intraneuronal amyloid in aged Alzheimer triple transgenic mice. Alzheimer Dis Assoc Disord 2015; 29(3): 184-91.
[http://dx.doi.org/10.1097/WAD.0000000000000075] [PMID: 25650693]
[28]
Chakroborty S, Briggs C, Miller MB, et al. Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer’s disease. PLoS One 2012; 7(12): e52056
[http://dx.doi.org/10.1371/journal.pone.0052056] [PMID: 23284867]
[29]
Muehlschlegel S, Sims JR. Dantrolene: Mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit. Neurocrit Care 2009; 10(1): 103-15.
[http://dx.doi.org/10.1007/s12028-008-9133-4] [PMID: 18696266]
[30]
Hanson LR, Frey WH II. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008; 9(3): S5.
[http://dx.doi.org/10.1186/1471-2202-9-S3-S5] [PMID: 19091002]
[31]
Zhang L, Andou Y, Masuda S, Mitani A, Kataoka K. Dantrolene protects against ischemic, delayed neuronal death in gerbil brain. Neurosci Lett 1993; 158(1): 105-8.
[http://dx.doi.org/10.1016/0304-3940(93)90623-S] [PMID: 8233063]
[32]
Shi Y, Zhang L, Gao X, et al. Intranasal dantrolene as a disease-modifying drug in Alzheimer 5XFAD mice. Alzheimers & Dementia 2019; 15(7): 597.
[33]
Xiao C, Davis FJ, Chauhan BC, et al. Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice. J Alzheimers Dis 2013; 35(4): 777-88.
[http://dx.doi.org/10.3233/JAD-122419] [PMID: 23542865]
[34]
Haraschak JL, Langston VC, Wang R, et al. Pharmacokinetic evaluation of oral dantrolene in the dog. J Vet Pharmacol Ther 2014; 37(3): 286-94.
[http://dx.doi.org/10.1111/jvp.12089] [PMID: 24219828]
[35]
Meredith ME, Salameh TS, Banks WA. Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases. AAPS J 2015; 17(4): 780-7.
[http://dx.doi.org/10.1208/s12248-015-9719-7] [PMID: 25801717]
[36]
Wang J, Shi Y, Yu S, et al. Intranasal administration of dantrolene increased brain concentration and duration. PLoS One 2020; 15 e0229156.
[PMID: 32160210]
[37]
Lacampagne A, Liu X, Reiken S, et al. Post-translational remodeling of ryanodine receptor induces calcium leak leading to Alzheimer’s disease-like pathologies and cognitive deficits. Acta Neuropathol 2017; 134(5): 749-67.
[PMID: 28631094]
[38]
Schrank S, McDaid J, Briggs CA, et al. Human-induced neurons from presenilin 1 mutant patients model aspects of Alzheimer’s disease pathology. Int J Mol Sci 2020; 21(3): 1030.
[PMID: 32033164]

Rights & Permissions Print Cite
Article Metrics
13
© 2024 Bentham Science Publishers | Privacy Policy